KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBIT Margin (2016 - 2025)

Teva Pharmaceutical Industries' EBIT Margin history spans 10 years, with the latest figure at 6.37% for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 737.0% year-over-year to 6.37%, compared with a TTM value of 12.49% through Dec 2025, up 1448.0%, and an annual FY2025 reading of 12.5%, up 1433.0% over the prior year.
  • EBIT Margin for Q4 2025 was 6.37% at Teva Pharmaceutical Industries, down from 19.69% in the prior quarter.
  • The five-year high for EBIT Margin was 19.69% in Q3 2025, with the low at 25.54% in Q2 2022.
  • Average EBIT Margin over 5 years is 1.86%, with a median of 4.14% recorded in 2021.
  • Year-over-year, EBIT Margin surged 12518bps in 2021 and then plummeted -4043bps in 2022.
  • Tracing TEVA's EBIT Margin over 5 years: stood at 1.9% in 2021, then plummeted by -1372bps to 24.2% in 2022, then surged by 170bps to 16.96% in 2023, then crashed by -106bps to 1.0% in 2024, then surged by 737bps to 6.37% in 2025.
  • Per Business Quant, the three most recent readings for TEVA's EBIT Margin are 6.37% (Q4 2025), 19.69% (Q3 2025), and 10.9% (Q2 2025).